header logo image


Page 1,008«..1020..1,0071,0081,0091,010..1,0201,030..»

Diabetes Burnout – KRCU

June 15th, 2017 9:47 pm

People with diabetes do not get to pick and choose when they want to deal with it. Diabetes is an ongoing disease that requires 24/7 work. But does having diabetes stop people from living their life to the fullest?

There are probably many different answers to that question. According to Ginger Vieira, the author of, Dealing with Diabetes Burnout, on a daily basis, she tries to balance three things: diabetes, life, and happiness.

Diabetes occurs when the pancreas is unable to produce enough insulin to control the bodys blood sugar levels. Because of the daily testing of blood sugar and the management of the disease through medication, activity and diet, people with diabetes can feel, as described by Linda Von Wartburg in Diabetes Health, ground down by the appalling endlessness of self-care. This causes burnout, which, in the context of diabetes, means ignoring blood sugar levels and neglecting the diet. This can harm a persons health and contribute to diabetes complications.

Experts advise making good enough the goal, rather than perfection when it comes to blood sugar readings. Striving for perfection can cause frustration, which can lead to people abandoning checking their sugar in fear of another bad reading. Other ways to avoid burnout include: learning more about diabetes, working with doctors to come up with a plan when you are overwhelmed by self-care, and joining diabetes support groups.

Although a person with diabetes may get burned out, they dont have to stay that way. Seeking help from health care providers, family and friends can get them back to living their life to the fullest.

Resources: Vieira, G. (2014). Dealing with diabetes burnout: how to recharge and get back on track when you feel frustrated and overwhelmed living with diabetes. New York: Demos Health. Von Wartburg, L. (2007). Diabetes Burnout. Diabetes Health, 16(3), 27-29. http://www.joslin.org/info/avoid_diabetes_burnout.html http://www.everydayhealth.com/hs/type-2-diabetes-live-better-guide/maintain-motivation/ http://www.diabetes.co.uk/emotions/diabetes-burnout.html

Content for this segment was created by Sidney Brockmeyer as part of a project for SC301: Foundations of Health Communication, taught by Ms. Clubbs.

Read more here:
Diabetes Burnout - KRCU

Read More...

‘The most infectious smile’: Nevada County mourns the death of 8-year-old Dawson Deschaine – The Union of Grass Valley

June 15th, 2017 9:45 pm

Breanna and Jason Deschaine are doing their best to keep smiling during a difficult time in their lives.

That's what their son Dawson would have wanted, they said.

Dawson died Saturday after two years of battling leukemia, a cancer that causes the body to produce too many immature white blood cells. He was eight years old.

"He always had a smile on his face," said his mom, Breanna. "It was the most infectious smile. So we're just smiling now, because that's all Dawson would want."

But he fought a hard battle for years. I was talking to his doctor today, and she told me she could always tell his tenacity and his drive to live every single day was just amazing.

Breanna Deschaine

Dawson became an honorary Nevada County firefighter last year during "Dawson's Day," a celebration of the bravery and courage he showed throughout his fight with leukemia.

Dawson rode around the county on a fire truck, and Grass Valley Fire Chief Mark Buttron honored him with a badge-pinning ceremony.

"We wanted to do something to show we appreciated how courageous he was," said Shawna Cresswell, Nevada County Consolidated Fire District's finance administrative assistant.

The Deschaine family helped Dawson experience a variety of exciting adventures in an effort to brighten his life. He'd spent countless hours in hospital beds since he was diagnosed with cancer at the age of five.

"He was always ready for whatever adventure we came up with," Breanna said. "He may have thought they were crazy afterward, but he was always super excited to go out and live his life to the fullest."

The Deschaines took Dawson white-water rafting, horseback riding, go-kart racing and mini golfing, among other adventures. It had been Dawson's dream to go to Hawaii, and the family is still planning to make that happen. Eventually, Breanna said, they will bring his ashes out with them on a family trip to the islands.

'Incredible' community support

Kelsey Anderson, a close friend of the Deschaine family, said she has been blown away by the amount of support the community has shown to Dawson, his parents and his 12-year-old sister Harlie.

"The support has been incredible," Anderson said. "Through the pain, the love shines through."

Anderson helped organize a variety of community events to raise money for the Deschaine family to pay for Dawson's many treatments.

During his fight with cancer, Dawson received chemotherapy treatments, radiation, and two stem cell transplants. He'd recently started a new drug trial that was said to be a possible cure for leukemia.

The family tried everything to help Dawson fight off his illness. But, according to Breanna, there isn't enough funding for childhood cancer treatments.

"Only 4 percent of cancer funding goes to childhood cancer," she said. "That's not enough for these kids that go through hell for years and years."

Support for those still fighting

The Deschaines have become close friends with other families who have children battling cancer. Breanna wants to help those kids who are still fighting. She said it's her mission to push for more research into childhood cancer treatments.

Breanna said she's not sure exactly what ended Dawson's battle with leukemia.

"His little heart and his little lungs just couldn't take it anymore," she said.

But as far as she's concerned, Dawson has won the fight. He's in a better place.

"We'd like to have him here. Trust me," she said. "But he fought a hard battle for years. I was talking to his doctor today, and she told me she could always tell his tenacity and his drive to live every single day was just amazing."

The Deschaine family will host a memorial service for Dawson at 4 p.m. July 2 at Western Gateway Park. Breanna said the ceremony will be open to anyone wishing to be a part of celebrating Dawson's life.

To contact Staff Writer Matthew Pera, email mpera@theunion.com or call 530-477-4231.

Read more:
'The most infectious smile': Nevada County mourns the death of 8-year-old Dawson Deschaine - The Union of Grass Valley

Read More...

Texas has sanctioned unapproved stem cell therapies. Will it change anything? – Science Magazine

June 15th, 2017 9:45 pm

Texas Governor Greg Abbott just signed a law making it easier for unproven stem cell therapies to be given to patients in his state.

Marjorie Kamys Cotera/Bob Daemmrich Photography/Alamy Stock Photo

By Kelly ServickJun. 15, 2017 , 11:15 AM

Texas Governor Greg Abbott yesterday signed a bill allowing clinics and companies in the state to offer people unproven stem cell interventions without the testing and approval required under federal law. Like the right to try laws that have sprung up in more than 30 states, the measure is meant to give desperately ill patients access to experimental treatments without oversight from the U.S. Food and Drug Administration (FDA).

In a state where unproven stem cell therapies are already offered widely with little legal backlash, bioethicists and patient advocates wonder whether the states official blessing will maintain the status quo, tighten certain protections for patients, or simply embolden clinics already profiting from potentially risky therapies.

You could make the argument thatif [the new law] was vigorously enforcedits going to put some constraints in place, says Leigh Turner, a bioethicist at the University of Minnesota in Minneapolis, who last year co-authored a study documenting U.S. stem cell clinics marketing directly to consumers online, 71 of which were based in Texas. But it would really be surprising if anybody in Texas is going to wander around the state making sure that businesses are complying with these standards, he adds. Either way, Turner says theres powerful symbolic value in setting up this conflict between state law and federal law.

The law, effective 1 September, will allow people with severe chronic or terminal illness to be treated at a clinic that purports to isolate therapeutic stem cells from adult tissuesuch as a patients own fatif their doctor recommends it after considering all other options, and if its administered by a physician at a hospital or medical school with oversight from an institutional review board (IRB). It also requires that the same intervention already be tested on humans in a clinical trial. The law sanctions a much broader set of therapies than federal rules, which already exempt certain stem cell interventions from FDAs lengthy approval process, provided the cells are only minimally manipulated and perform the same function they normally have in body.

The Texas bills clinical trial and IRB requirements seem to weed out some dubious therapies, but the language is too nebulous to protect patients, says Beth Roxland, a bioethicist at New York Universitys Langone Medical Center in New York City. The bill doesnt specify that a trial be conducted in the United States or that the therapy get clearance from FDA for human testing. You could gain access to something [as long as its] being studied in a human somewhere on the planet, she says, which in the stem cell area makes it really very scary.

Awareness about the risks of unproven stem cell therapies is growing. A case report published in The New England Journal of Medicine earlier this year documented three women who lost their vision after receiving purported stem cell injections meant to treat age-related degeneration of the retina. Such risks are also the subject of a news conference today at the annual meeting of the International Society for Stem Cell Research in Boston.

Roxland is also unnerved by a provision in the Texas law that would prevent any state government entity from interfering with a patients access to treatment. Hypothetically, if a state officially gets wind of nefarious doings at a for-profit clinic the state officials are now restrained from doing anything. She notes that that language mirrors a proposal in a federal bill known as the Trickett Wendler Right to Try Act, introduced in the Senate in January, which would prevent the federal government from interfering with a terminally ill patients access to an experimental drug outside of a clinical trial, and would prevent FDA from considering those patients outcomes in its drug approval decisions. Vice President Mike Pence signaled his support for the law in February and met with the family of Trickett Wendler, who advocated for right to try laws before her death from amyotrophic lateral sclerosis in 2015.

Others also believe that the Texas laws approval might signal a coming thaw in federal regulation of stem cell clinics. The FDA obviously doesnt have the manpower to watch over these people, says David Bales, chairman of the advocacy group Texans for Cures in Austin, which pushed for more patient protections in the new bill. We really feel like theyre trying to open up the floodgates.

Read the original here:
Texas has sanctioned unapproved stem cell therapies. Will it change anything? - Science Magazine

Read More...

Many unaware that smoking causes blindness – AOP

June 15th, 2017 9:44 pm

New research found that 53% of respondents did not know about the link between smoking and blindness

15 Jun 2017 by Emily McCormick

A recent survey by the Macular Society reports that 53% of people are unaware that smoking can cause blindness.

The national charity performed the survey ahead of Macular Week at the end of the month (26 June 2 July), which aims to raise public awareness about age-related macular degeneration (AMD) the largest cause of sight loss in the UK.

The Macular Society highlights smoking as the biggest modifiable risk factor in the development of AMD and reports that smokers are four times more likely to develop the condition when compared to non-smokers.

During Macular Week the charity will focus on raising awareness about the harmful effects that smoking can have on the eyes, stressing that this includes passive smoking.

Explaining the cause and affect, the charity detailed that tobacco smoke contains toxic chemicals that are transported to the delicate tissues of the eye through the blood stream where they can damage the structure of the cells.

Chief executive of the Macular Society, Cathy Yelf, said: It is surprising how many people do not realise that smoking causes blindness. The message is often missing from anti-smoking messages, which simply concentrate on the life-threatening side effects of smoking. Sight loss, however, is a very important effect of smoking.

Ms Yelf emphasised that smoking is incredibly bad for your eyes, adding: You could be 20 or more times more likely to get macular disease if you have those certain genes and you smoke.

Read this article:
Many unaware that smoking causes blindness - AOP

Read More...

This Biotechnology Company Wants to Reanimate the Brain-Dead – TrendinTech

June 15th, 2017 9:44 pm

Ira Pastor, CEO of Bioquark, a Philadelphia-based biotechnology company, believes we will on day be able to reset the brain of patients declared brain-dead using a series of stem cell injections and nerve stimulations.

Until recently, death was medically defined as a loss of heart and lung function but as medical technology has advanced so has the qualifications. Now, since both heartbeat and breathing functions can be performed for a patient by machine, death is almost universally declared when there is a loss of activity in the brain stem. However, Pastor does think that this loss of brain function is as irreversible as weve come expect.

Initially, Bioquark was slated to start trials for the procedure last year in India but, due to strong opposition by the Indian Council of Medical Research, those studies were canceled. Nevertheless, Ira Pastor and his collaborator Himanshu Bansal, an orthopedic surgeon, remain undaunted and have announced a new series of test to happen soon in a nameless South American country.

Although they have not released the details of the revolutionary procedure, we can gather a general idea of their plan to reanimate the brain-dead from the papers regarding their original canceled trial.

Originally, the researchers wanted brain-dead subjects between the ages of 12 and 65. Ideally, the cause of the brain damage would be due to traumatic injury. Scientists would look at MRIs to determine eligibility, then brain cells would be harvested from the patients blood. After the stem cells are injected, the patients would get another injection, this time peptides, directly to the spinal column. The series of injections is followed by two weeks of nerve stimulation, specifically the median nerve, by lasers, which Bioquark thinks is the key to reversing brain death.

Bioquark has not clarified how it intends to obtain consent from technically dead patients but in spite of the controversy, this study is not alone. The work at Bioquark is part of a larger program concerning neuro-reanimation and regeneration called ReAnima.

Pastor, who also serves on the advisory board for the project, told the Daily Mail: The mission of the ReAnima Project is to focus on clinical research in the state of brain death, or irreversible coma, in subjects who have recently met the Uniform Determination of Death Act criteria, but who are still on cardio-pulmonary or trophic support a classification in many countries around the world known as a living cadaver.

More News to Read

comments

See more here:
This Biotechnology Company Wants to Reanimate the Brain-Dead - TrendinTech

Read More...

Biotechnology expert proposed for top Chinese University of Hong Kong post – South China Morning Post

June 15th, 2017 9:44 pm

An internationally renowned biotechnology scientist, Professor Rocky Tuan Sung-chi, has been recommended to succeed Joseph Sung Jao-yiu as Chinese University vice-chancellor.

Born in Hong Kong and educated in the United States, Tuan is currently working at the University of Pittsburgh as director of the institutions cellular and molecular engineering lab, executive vice-chairman of the Department of Orthopaedic Surgery and a professor in the Department of Bioengineering.

He has been serving as a distinguished visiting professor and director of the Institute for Tissue Engineering and Regenerative Medicine at Chinese University.

The institutions council said on Thursday that it would recommend Tuan to be the next vice-chancellor. It will hold a consultation of up to six weeks with staff, students and alumni, but the universitys teachers association vowed to boycott it, saying the council had fooled it by saying it was not sure who the candidate was.

In May 2016, Tuan was one of the 10 Carnegie Science Award winners for his extensive experience in applying adult stem cells for tissue engineering and regenerative medicine.

Hes a good scientist, professionally speaking, with a major interest in bone and tendon regeneration, Professor Chan Wai-yee of the universitys School of Biomedical Sciences said. He used to chair the biology and medicine panel of the Research Grants Council so he should know better than others what improvements can be made to develop Hong Kongs scientific research.

I have high expectations of him. As a successful scholar who has worked for the Research Grants Council for so many years, he could at least reflect our wish for more funding and resources.

However, Professor Chan King-ming, president of the Chinese University Teachers Association, said he was angry about the announcement and that staff and students were being played by the universitys top administration, who two weeks ago told the association they were still not sure about the candidate.

Chan King-ming also said Tuan lacked outstanding academic status and administrative experience. Seldom were his papers published by top journals and he has never served at the level of deputy vice-chancellor or dean in any university, the biochemistry scholar said.

Continued here:
Biotechnology expert proposed for top Chinese University of Hong Kong post - South China Morning Post

Read More...

Vontobel Swiss Wealth Advisors AG Acquires 4956 Shares of iShares Nasdaq Biotechnology Index Fund (IBB) – The Cerbat Gem

June 15th, 2017 9:44 pm
Vontobel Swiss Wealth Advisors AG Acquires 4956 Shares of iShares Nasdaq Biotechnology Index Fund (IBB)
The Cerbat Gem
iShares Nasdaq Biotechnology Index Fund logo Vontobel Swiss Wealth Advisors AG increased its position in shares of iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) by 36.0% during the first quarter, according to its most recent 13F filing with the ...
Ken Stern & Associates Inc. Has $318000 Stake in iShares Nasdaq Biotechnology Index Fund (IBB)Stock Observer
iShares Nasdaq Biotechnology Index Fund - Receive News & Ratings DailyBBNS
The Traders Buy Large Volume of Put Options on iShares Nasdaq Biotechnology Index Fund (IBB)BangaloreWeekly

all 7 news articles »

Link:
Vontobel Swiss Wealth Advisors AG Acquires 4956 Shares of iShares Nasdaq Biotechnology Index Fund (IBB) - The Cerbat Gem

Read More...

Johnson & Johnson unveils new obesity, arthritis collaborations … – FierceBiotech

June 15th, 2017 9:44 pm

Johnson & Johnsons Innovation unit has unveiled another clutch of deals and collaborations with industry and academia, as it also shares its molecular library to help fight neglected diseases.

J&Js Innovation unit has more than 300 collaborative pacts to its nameand started the year with 15 more that focused on a biotech NASH deal with Bird Rock Bio, while also bumping up its work on malaria and penning another RNA deal with Synthetic Genomics.

RELATED: J&J in New Year deal mania, takes on NASH candidate with biotech buyout option

Six months down the line and timed to coincide at this years BIO Convention, its at it again, with its R&D unit Janssen inking a multiproject collab with the University of California San Diego School of Medicinefocused on fatty liver disease/obesity.

Plans are in place to work on finding pathways and mechanisms driving disease progression, as well as clinically useful biomarkers, targets and gastric bypass approaches, all of which is designed to find new therapies for NASH, chronic kidney disease (CKD) and other obesity-based conditions.

Projects under this collaboration will include exploration of animal and cell models of NASH and CKD, discovery of mechanisms invoked by bariatric surgery, disease-related biomarkers and novel therapeutic targets, J&J said in a statement.

Building on its blockbuster work in rheumatoid arthritis (RA), and coming as a host of biosimilars line up to erode sales from older meds, Janssen Biotech has also formed a multiyear collaborationand prenegotiated option-to-license agreementwith Monash University to discover and develop next-gen biologics to treat, prevent and intercept RA. As is usual with these deals, dollar terms have not been disclosed.

And building on its work in malaria and other neglected diseases, Janssen has penned pacts aimed at speeding up the discovery of new treatments for tuberculosis, malaria, neglected tropical diseases, and other diseases prevalent in the developing world.

It will help by sharing selected parts of its molecular libraries with governmental biomedical research agenciessuch as the U.S. National Institute of Allergy and Infectious Diseases of the National Institutes of Health and academic centers such as Washington University in St. Louis, the University of California, Berkeley, and the Center for Discovery and Innovation in Parasitic Diseases at the University of California San Diego.

Through WIPO Re:Search, the international research consortium led by the nonprofit BIO Ventures for Global Health and the United Nations World Intellectual Property Organization, Janssen says it will open up segments of its molecule library, which hold a set of 80,000 chemical compounds, to these organizations to help seek out and push on with promising drug candidates.

By working collectively, the global health community can increase and accelerate the potential to achieve major research breakthroughs for the millions of people worldwide who suffer from these devastating diseases, said Wim Parys, M.D., head of R&D Global Public Health at Johnson & Johnson, in a release.Opening our compound libraries and providing our partners access to the research capabilities of the Johnson & Johnson family of companies underscores our commitment to accelerate the pace of innovation to broaden our reach and deepen our impact.

See the original post:
Johnson & Johnson unveils new obesity, arthritis collaborations ... - FierceBiotech

Read More...

Novartis’ Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis – FiercePharma

June 15th, 2017 9:44 pm

The ankylosing spondylitis and psoriatic arthritis markets are growing increasingly crowded, but Novartis now has something not all its rivals can boast: long-term data for its IL-17 med, Cosentyx.

Thursday at the Annual European Congress of Rheumatology in Madrid, the Swiss drugmaker unveiled study results showing its contender could show sustained improvements in signs and symptoms of both maladies.

In one extension trial, at three years, 80% of ankylosing spondylitis patients taking Cosentyx hit the 20 mark on the Assessment of Spondyloarthritis International Society response criteria scale.

And a new analysis of Novartis Future 2 study showed that by the two-year point, 28% of psoriatic arthritis patients treated with Cosentyxalmost all of whom had reported moderate-to-extreme pain or discomfort before starting on the drugfelt no pain or discomfort at all.

RELATED:Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals

Its good news for Novartis, whose med is currently the only member of the IL-17 crowd to boast indications in ankylosing spondylitis and psoriatic arthritis. Knowing competition was on the way, the company worked to snag those a year after winning Cosentyx initial nod in psoriasis.

Since then, Novartis has been joined by Eli Lillys Taltz and Valeants Siliq, and development of other candidatessuch as Johnson & Johnsons guselkumabis underway. Lilly, for one, currently has Taltz in phase 3 as a treatment for axial spondyloarthritis, an umbrella that includes ankylosing spondylitis.

But its not only IL-17 products competing for a slice of the pie. Pfizer is developing its rheumatoid arthritis pill, Xeljanz, for psoriatic arthritis, and Celgene's psoriasis pill Otezla has a psoriatic arthritis nod, as well. On the ankylosing spondylitis front, J&Js Stelara could eventually challenge Cosentyx, research and consulting firm GlobalData has predicted.

Read this article:
Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis - FiercePharma

Read More...

New Phase 3 Data Shows Golimumab Significantly Improved Arthritis and Skin Manifestations in Patients with Active RA – Drug Discovery &…

June 15th, 2017 9:44 pm

Janssenannounced results from the pivotal Phase 3 GO-VIBRANT study that showed the significant efficacy of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI ARIA(golimumab) in the treatment of active psoriatic arthritis. In GO-VIBRANT, 75.1 percent of patients with active psoriatic arthritis receiving SIMPONI ARIA2 mg/kg achieved at least a 20 percent improvement in arthritis signs and symptoms as measured by the American College of Rheumatology (ACR20) at week 14, the studys primary endpoint, compared with 21.8 percent of patients receiving placebo (P< 0.001). SIMPONI ARIAalso showed significant improvement across all secondary endpoints evaluating improvements in skin symptoms, joint damage and health-related quality of life measures. Data from GO-VIBRANT are being presented for the first time at the Annual European Congress of Rheumatology (EULAR) 2017. SIMPONI ARIAis currentlyunder reviewby the U.S. Food and Drug Administration (FDA) for the treatment of adults with active psoriatic arthritis and the treatment of adults with ankylosing spondylitis. SIMPONI ARIAis approved in the U.S. for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate.

Results from the GO-VIBRANT study showed that treatment with intravenous golimumab improved joint and skin symptoms in patients with active psoriatic arthritis, and inhibited the progression of structural damage, which are important treatment goals in the management of this progressive, inflammatory disease, said Arthur Kavanaugh, MD, Professor of Medicine, University of California San Diego, and Chair of the GO-VIBRANT steering committee. Intravenously administered golimumab could represent an important new anti-TNF-alpha therapy for rheumatologists to consider in the treatment of active psoriatic arthritis in the future. Treatment with SIMPONI ARIAat weeks 0 and 4 and every eight weeks thereafter resulted in statistically significant improvements in all secondary endpoints presented below (P< 0.001 for all measures).

At week 14

At week 24

Through week 24, 46.3 percent of SIMPONI ARIA-treated patients and 40.6 percent of placebo-treated patients reported at least one adverse event (AE). Serious AEs were reported by 2.9 percent of patients receiving SIMPONI ARIAvs. 3.3 percent for placebo. Two deaths and two malignancies were reported, all in the placebo group, and one demyelinating event occurred in the SIMPONI ARIAgroup. The most common treatment-emergent type of AE was infection, identified in 20.0 percent of SIMPONI ARIA-treated patients compared to 13.8 percent of placebo-treated patients. There was no opportunistic infection or tuberculosis through week 24. The rate of infusion reactions with SIMPONI ARIAwas less than 2 percent and none were serious or severe.

At Janssen, our commitment to rheumatology began more than two decades ago with discovery, development and approval of the first anti-TNF-alpha therapy, and since then, we have continued to build upon our portfolio of medicines for patients with immune-mediated diseases, said Newman Yeilding, M.D., Head of Immunology Development, Janssen Research & Development, LLC. Data from the GO-VIBRANT study demonstrated how SIMPONI ARIA, a product already helping people living with moderately to severely active rheumatoid arthritis, may also help those living with psoriatic arthritis, pending its approval in the U.S.

Additional SIMPONI ARIAdata being presented at EULAR 2017 includes findings from the Phase 3 ankylosing spondylitis GO-ALIVE study:

Continued here:
New Phase 3 Data Shows Golimumab Significantly Improved Arthritis and Skin Manifestations in Patients with Active RA - Drug Discovery &...

Read More...

Arthritis drug shows promise in combatting protein that causes aortic valve stenosis – Cardiovascular Business

June 15th, 2017 9:44 pm

Development of a drug to help those suffering from rheumatoid arthritis may prove to be quite a happy accident for aging individuals with hardening heart valves. Researchers from Vanderbilt University announced promising results in examining a monoclonal antibodys ability to combat aortic valve stenosis.

The results, published June 12 in Circulation, could be an important step toward fighting the condition that affects a quarter of Americans over the age of 65, who previously only had surgical replacement of valves as an option.

Very elderly patients bodies cant handle that, said first author Cyndi Clark, research assistant professor of biomedical engineering at Vanderbilt. I hope to see an earlier treatment option available within the next decade.

The drug, known as SYN0012, appeared to bind to cadherin-11 (CDH-11), a protein that causes the hardening of valve tissue.

The antibody we're working with blocks fibroblasts from becoming the active type that leads to disease. It keeps them from becoming inflamed, said W. David Merryman, associate professor of biomedical engineering at Vanderbilt. "We believe there is potential for using this drug at the first sign of valve disease to prevent the progression. You likely cannot reverse the damage, but we believe the drug can prevent it."

The drug is in human clinical trials for treatment of rheumatoid arthritis. After those are complete, Merryman hopes to gain permission to run clinical trials for uses in heart valve disease. His work is funded by a $5.3 million award from the National Heart, Lung and Blood Institute.

More:
Arthritis drug shows promise in combatting protein that causes aortic valve stenosis - Cardiovascular Business

Read More...

New Law Opens Door for Stem Cell Therapy in Texas – Spectrum News

June 15th, 2017 9:43 pm

AUSTIN, Texas -- The legal battle to get patients access to stem cell therapy in Texas is closer to reality.

Gov. Greg Abbott signed such legislation into law this week, and itmeans some patients will be heading into uncharted medical territory.

Come Sept. 1, patients with terminal illnesses or severe chronic diseases will be allowed to access experimental stem cell treatments in Texas.

MORE |Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments

Currently, mostpatients who want stem cell therapy have to travel outside the United States to do it, and stem cell re-injections are only allowed here within a 24-hour window.

"This is going to protect patient health, and provide for the treatments to be done here locally at home," saidMike Byrom, the Chief Science Officer at Austin stem cell bankBioEden.

Byrom said the new lawwill keep patients in the country, and will provide renewed hope for those with serious ailments.

This hope resulted in anemotional fight this session.

Texas State Rep. Drew Springer, R-Gainesville, gave an impassioned speech for the legislation as the deadline to read new bills approached, urging lawmakers to keep it from dying.

"I'll be damned if we don't get the chance tonight to hear the very next bill that opens up the doors of medical science," saidSpringer, whose wife is wheelchair-bound."It might give somebody like my wife a chance to walk."

But not everyone's convinced this is the right way to go.

"We want access for patients to the best drugs, but we think they ought to go through the FDA approval process," saidTexans for Cures Chairman David Bales.

Bales was one of the few people who testified against the bill. While he supports more stem cell research,hearguesthe state should fund it, rather than letting for-profit businesses lead the way.

"You run the risk of medical fraud because a lot of these guys, a lot of these patients, are paying a lot of money, to physicians and drug manufacturers who haven't gone through the right process,"Balessaid.

Patients who will be participating in stem cell therapy procedures will give up their right to take legal action if something goes wrong.

---

Join the Discussion:

Follow Capital Tonight Texas on Facebook & Twitter

Keep the conversation going on our political blog: Capital Roundup .

Continue reading here:
New Law Opens Door for Stem Cell Therapy in Texas - Spectrum News

Read More...

Milestones in living with blindness in the modern day | A Different … – Walla Walla Union-Bulletin

June 15th, 2017 1:45 am

Have you ever thought about how people in the modern day have dealt with being blind?

I did some research and learned a lot. Following are some bits of information you may find interesting.

1829: Louis Braille publishes his system of writing the French language. Its 1837 revision was the first modern binary writing form developed.

1832: The Perkins School for the Blind in Boston admitted its first two students sisters Sophia and Abbey Carter.

Perkins manufactures its own Perkins Brailer, which is used to print embossed, tactile books for the blind.

1860: Simon Pollak demonstrates the use of Braille at the Missouri School for the Blind.

1861: Helen Adams Keller is born in Tuscumbia, Ala.

1864: The enabling act giving the Columbia Institution for the Deaf and Blind the authority to confer college degrees is signed by President Abraham Lincoln, making it the first college in the world expressly established for people with disabilities. Columbia University, its name later changed to Gallaudet University, is in Washington, D.C.

1878: Joel W. Smith presents his Modified Braille to the American Association of Instructors of the Blind. The association rejects his system, continuing to endorse instead New York Point, which blind readers complain is more difficult to read and write.

What followed was a War of the Dots in which blind advocates for the most part preferred Modified Braille, while sighted teachers and administrators, who controlled the funds for transcribing, wanted New York Braille.

1909: The New York Public School System adopts Modified or American Braille for use in its classes for blind children, after public hearings in which blind advocates call for abandoning New York Point.

1909: The first folding wheelchairs are introduced for people with mobility disabilities.

1921: The American Foundation for the Blind is founded. Helen Keller is its principal fundraiser.

1929: Seeing Eye establishes the first guide dog school for blind people in the United States. Today, this well-known guide dog school is in Morristown, N.J.

1932: The Treaty of London standardizes American and English Braille.

1933: Franklin Delano Roosevelt, the first seriously physically disabled person ever to be elected as a head of government, is sworn into office as president of the United States. He chooses to minimize his disability in response to the ableism of the electorate.

1936: Passage of the Randolph Sheppard Act establishes a federal program for employing blind vendors at stands in the lobbies of federal office buildings.

1937: Herbert A. Everest and Harry C. Jennings patent a design for a folding wheelchair with an X-frame that can be packed into a car trunk.

1940: The National Federation of the Blind is formed in Wilkes-Barre, Pa., by Jacobus Broek and other blind advocates. Among other reforms, it pushes for white cane laws and input by blind people into programs for blind clients.

Since 1942: Guide Dogs for the Blind (GDB) has created partnerships between people, dogs and communities. With client services and a network of instructors, puppy raisers, donors and volunteers, the agency prepares highly qualified guide dogs to serve and empower individuals who are blind or have low vision throughout the United States and Canada.

All services for GDBs clients are provided free of charge, including personalized training and extensive post-graduation support, plus financial assistance for veterinary care, if needed. GDB has two campuses in San Rafael, Calif., and Boring, Ore.

1943: Congress passes the Vocational Rehabilitation Amendments, known as the LaFollette-Barden Act, adding physical rehabilitation to the goals of federally funded vocational rehabilitation programs and providing funding for certain health care services.

1945: The Blinded Veterans Association is formed in Avon, Conn. Its mission is to promote the welfare of blinded veterans so that, notwithstanding their disabilities, they may take their rightful place in the community and work with fellow citizens toward the creation of a peaceful world.

1961: The American Council of the Blind is formally organized. ACB strives to increase the independence, security, equality of opportunity and quality of life, for all blind and visually impaired people.

1963: John Hessler joins Ed Roberts at the University of California at Berkeley, other disabled students follow. Together they form the Rolling Quads to advocate for greater access on campus and in the surrounding community.

1968: The Architectural Barriers Act is passed by Congress, mandating federally constructed buildings and facilities be accessible to all people.

The ABA requires access for everyone whether blind or with any other disability to have access into any facilities designed, built, altered or leased with federal funds.

This marks one of the first efforts to ensure access to the constructed environment for all people.

Blindness or visual impairment can have a profound impact on your life, but you are still in control there is an abundance of information to help you.

Ernie Jones, a registered nurse who retired due to vision loss, can be reached at 529-9252 or eajsr37@outlook.com.

Follow this link:
Milestones in living with blindness in the modern day | A Different ... - Walla Walla Union-Bulletin

Read More...

Prevent Blindness Works to Educate the Public on the Dangers of … – Benzinga

June 15th, 2017 1:45 am

Prevent Blindness Provides Alternative Ideas on Ways Families Can Celebrate Independence Day Safely

CHICAGO (PRWEB) June 14, 2017

The U.S. Consumer Product Safety Commission (CPSC), estimated that injuries from fireworks sent 8,000 Americans to the emergency room over the Fourth of July holiday. The latest CPSC annual report stated that forty-two percent of the estimated emergency department-treated, fireworks-related injuries were to individuals younger than 20 years of age. Sadly, the CPSC also reported 11 non-occupational fireworks-related deaths.

The American Pyrotechnics Association states that Delaware, Massachusetts and New Jersey are the only states that ban all consumer fireworks. Fireworks laws vary from state to state and sometimes, within different counties.

A recent study, "Effect of Fireworks Laws on Pediatric Fireworks-Related Burn Injuries," published in the Journal of Burn Care & Research, concluded that the relaxing of fireworks laws in the United States has had a dramatic effect on the severity of the related injuries, resulting in more inpatient admissions and longer length of stay in the hospital.

Yet despite the thousands of injuries and consumer firework-related deaths, some state government representatives are moving to lift restrictions on consumer fireworks.

In fact, in Iowa, a new law enacted in April allows retail sales of consumer fireworks in permanent buildings between June 1 and July 8, and again between Dec. 10 and Jan. 3.

As a public health-based organization, Prevent Blindness supports the development and enforcement of bans on the importation, sale and use of all fireworks and sparklers, except those used in authorized public displays by competent licensed operators. The national non-profit group, including its affiliates, works with leading organizations to educate the public on the dangers of consumer fireworks and endorses legislation to help protect adults and children from needless injuries from fireworks.

The CPSC states that burns from fireworks are the most common injury to all parts of the body, except the eyes, where contusions, lacerations, and foreign bodies in the eyes occurred more frequently. According to the American Academy of Pediatrics, approximately one third of eye injuries from fireworks result in permanent blindness.

Prevent Blindness, the nation's oldest volunteer eye health and safety organization, offers alternatives to celebrate the holiday safely:

"The Fourth of July can still be fun without fireworks," said Hugh R. Parry, president and CEO of Prevent Blindness. "By attending only fireworks shows run by licensed professionals, and being vigilant, we can celebrate our nation's birthday with family and friends, not in the emergency room."

For more information on the dangers of fireworks, please call Prevent Blindness at (800) 331-2020, or visit preventblindness.org/prevent-eye-injuries-fireworks.

About Prevent Blindness Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, or to make a contribution to the sight-saving fund, call 1-800-331-2020. Or, visit us on the Web at preventblindness.org or facebook.com/preventblindness.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14422232.htm

Read the original:
Prevent Blindness Works to Educate the Public on the Dangers of ... - Benzinga

Read More...

Biotechnology company opens mosquito factory in Lexington … – Lexington Herald Leader

June 15th, 2017 1:45 am

Lexington Herald Leader
Biotechnology company opens mosquito factory in Lexington ...
Lexington Herald Leader
A Lexington biotechnology company aimed at fighting mosquito-borne diseases such as the Zika virus opened a mosquito factory Friday on Malabu Drive.

and more »

Read the original:
Biotechnology company opens mosquito factory in Lexington ... - Lexington Herald Leader

Read More...

Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.13 Per Share – The Cerbat Gem

June 15th, 2017 1:45 am

NormanObserver.com
Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.13 Per Share
The Cerbat Gem
Puma Biotechnology logo Equities analysts expect that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings of ($2.13) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Puma ...
Right After Earnings, The Intelligent Options Trade in Puma Biotechnology IncCML News
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at Stifel NicolausSports Perspectives
The Puma Biotechnology Inc (PBYI) Downgraded by Zacks Investment Research to HoldBangaloreWeekly
BBNS -Transcript Daily -Chaffey Breeze -SEC.gov
all 88 news articles »

See the rest here:
Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.13 Per Share - The Cerbat Gem

Read More...

Rheumatoid arthritis: Being overweight might NOT be a risk factor in … – Express.co.uk

June 15th, 2017 1:45 am

GETTY

The autoimmune condition is caused by the immune system attacking healthy body tissue.

However, researchers explored whether high body fat and large waist size were a risk factor.

In the study, presented this week to the Annual European Congress of Rheumatology 2017, they found no clear association between rheumatoid arthritis (RA) and being overweight or obese in men.

However, for women, being overweight or obese was linked to a higher likelihood of developing it.

GETTY

This conflicts with previous studies that found an association for both genders between rheumatoid arthritis and being overweight or obese.

This conflicts with previous studies that found an association for both genders.

Dr. Asta Linauskas, lead study author from University Hospital, Aarhus in Denmark, said: One possible explanation for these inconsistencies is that while BMI has been the preferred surrogate measure for being overweight in these studies, BMI only correlates modestly with total amount of body fat and does not accurately reflect fat distribution.

"Our results support an association between the risk of developing RA and three different criteria for being overweight or obese in women.

We believe RA should be included in the list of all the other medical conditions linked to obesity. It would certainly make sense for women with a family history of RA to try to avoid becoming overweight.

Getty

1 of 12

GETTY

In the study, they looked at 54,284 people - 52 per cent women - between the ages of 50 and 64 years at the time of recruitment between 1993 and 1997.

During a median follow up of 21 years, 283 women and 110 men developed RA.

The median time for onset of the condition was seven years.

In the data, a positive slope in women confirmed a direct relationship, but there was no such linear association in men.

GETTY

According to the NHS, other possible risk factors include genetics, hormones and smoking.

As well as joint pain, symptoms can include sweating, a poor appetite and weight loss.

The condition can be difficult to diagnose as many conditions cause joint stiffness and inflammation.

However, once diagnosed, treatment can be used to enable you still stay as active as possible.

Link:
Rheumatoid arthritis: Being overweight might NOT be a risk factor in ... - Express.co.uk

Read More...

‘Advances made in stem cell therapy in Asia far more than those made in US’ – The Hindu

June 15th, 2017 1:44 am
'Advances made in stem cell therapy in Asia far more than those made in US'
The Hindu
Indigenously developed therapeutic modules for neuro development disorders like autism have demonstrated a higher rate of recovery and improvement among sufferers, Nandini Gokulchandran, a Mumbai-based researcher in the field of stem cell therapy ...

Original post:
'Advances made in stem cell therapy in Asia far more than those made in US' - The Hindu

Read More...

Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments – Spectrum News

June 15th, 2017 1:44 am

AUSTIN, Texas -- Gov. Greg Abbott has signed a new law that allows terminally ill or those which chronic diseases receive stem cell treatments in Texas.

Stem cell therapy is the use of stem cells to treat or prevent a disease or condition, and is often patient's last hope for improvement.

Bone marrow transplant is the most widely used stem-cell therapy, and can often help those with multiple sclerosis and other diseases.

House Bill 810, which was introduced by Rep. Tan Parker, R-Flower Mound, passed in both the Texas House and Senate.

"It is easy to fall into the trap of viewing legislation as just words on a piece of paper," said Sen. Paul Bettencourt, R-Houston, the bill's sponsor in the Senate. "But for the many people who are ill with multiple sclerosis and other diseases that stem cell therapy has the hope of solving in our lifetime, I look at this bill, I look at the possibility of what can happen in the 21st Century, with Texas taking the lead on adult stem cell treatments and this bill has the potential to extend lives and make a difference for these patients."

The Texas Medical Board will be responsible for writing the rules for the treatment.

"Everyone has a zest for life. This adult stem cell treatment possibility gets government out of the way to let these new therapies flourish and give these patients hope for a future good quality of life," Bettencourt added.

The legislation takes effect Sept. 1.

-- Value of Stem Cell Therapy --

According to the National Institues of Health, stem cellshave the remarkable potential to develop into many different cell types in the body during early life and growth.

In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive.

When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Doctors say stem cells are important for living organisms for many reasons.

In the 3- to 5-day-old embryo, called ablastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lungs, skin, sperm, eggs and other tissues.

In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease.

---

Join the Discussion:

Follow Spectrum News Austin on Facebook | Twitter | Instagram

Read the original post:
Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments - Spectrum News

Read More...

Family’s mission to raise profile of type one diabetes – BBC News

June 14th, 2017 12:48 am

BBC News
Family's mission to raise profile of type one diabetes
BBC News
The family of a teenager who died from type one diabetes has made it "their mission" to raise the profile of the condition. Peter Baldwin, 13, from Cardiff, died in 2015, just days after he was diagnosed. His family are working closely with Diabetes UK ...

and more »

Continued here:
Family's mission to raise profile of type one diabetes - BBC News

Read More...

Page 1,008«..1020..1,0071,0081,0091,010..1,0201,030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick